Early-stage follicular lymphoma (FL) can be cured with involved-field radiotherapy (IF-RT); however, many patients relapse in non-irradiated areas. A combined association with chemotherapy could increase treatment efficacy, but toxic effects could be unacceptable. In vitro synergistic effect between rituximab (R) and RT has been observed, but clinical data are limited. We retrospectively analyzed 41 early-stage FL patients receiving R and IF-RT as first-line treatment. We administered R 375mg/m2weekly for four courses, before or after IF-RT (median dose 24 Gy). Primary outcome was PFS, secondary endpoints were CR rate, OS and safety. All patients achieved CR, after a median follow-up of 46 months only three patients relapsed after 18, 26 and 42 months; estimated 5-year PFS was 90%. We suggest R in association with IF-RT could represent a feasible first-line treatment option for early-stage FL and could increase efficacy without additional toxicity compared to available data about RT alone.

Cencini, E., Puccini, B., Rigacci, L., Fabbri, A., Kovalchuk, S., Mannelli, L., et al. (2018). Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma. LEUKEMIA & LYMPHOMA, 59(6), 1420-1426 [10.1080/10428194.2017.1387909].

Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma

Cencini, Emanuele;Carfagno, Tommaso;Bocchia, Monica
Supervision
;
Bosi, Alberto
2018

Abstract

Early-stage follicular lymphoma (FL) can be cured with involved-field radiotherapy (IF-RT); however, many patients relapse in non-irradiated areas. A combined association with chemotherapy could increase treatment efficacy, but toxic effects could be unacceptable. In vitro synergistic effect between rituximab (R) and RT has been observed, but clinical data are limited. We retrospectively analyzed 41 early-stage FL patients receiving R and IF-RT as first-line treatment. We administered R 375mg/m2weekly for four courses, before or after IF-RT (median dose 24 Gy). Primary outcome was PFS, secondary endpoints were CR rate, OS and safety. All patients achieved CR, after a median follow-up of 46 months only three patients relapsed after 18, 26 and 42 months; estimated 5-year PFS was 90%. We suggest R in association with IF-RT could represent a feasible first-line treatment option for early-stage FL and could increase efficacy without additional toxicity compared to available data about RT alone.
Cencini, E., Puccini, B., Rigacci, L., Fabbri, A., Kovalchuk, S., Mannelli, L., et al. (2018). Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma. LEUKEMIA & LYMPHOMA, 59(6), 1420-1426 [10.1080/10428194.2017.1387909].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11365/1030453